Daily Cardiology Research Analysis
Three cardiology studies stand out today: a phase 3 RCT shows sotatercept significantly reduces death/transplant/hospitalization in high-risk pulmonary arterial hypertension; a phase 2 RCT demonstrates robust LDL-C lowering with a first-in-class oral small-molecule PCSK9 inhibitor; and a 20-year European cohort validates universal one-time screening of LDL-C, hsCRP, and Lp(a) to predict cardiovascular events.
Summary
Three cardiology studies stand out today: a phase 3 RCT shows sotatercept significantly reduces death/transplant/hospitalization in high-risk pulmonary arterial hypertension; a phase 2 RCT demonstrates robust LDL-C lowering with a first-in-class oral small-molecule PCSK9 inhibitor; and a 20-year European cohort validates universal one-time screening of LDL-C, hsCRP, and Lp(a) to predict cardiovascular events.
Research Themes
- Advanced therapies for pulmonary arterial hypertension
- Oral PCSK9 inhibition for hypercholesterolemia
- Primary prevention risk stratification with LDL-C, hsCRP, and Lp(a)
Selected Articles
1. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
In a phase 3 randomized trial of advanced, high-risk PAH on maximal background therapy, add-on sotatercept reduced the composite of death, lung transplantation, or ≥24-hour hospitalization versus placebo (17.4% vs 54.7%; HR 0.24). Adverse events included epistaxis and telangiectasia.
Impact: This is a practice-changing RCT demonstrating substantial event reduction in a population with few options (WHO III/IV PAH at high risk), extending sotatercept’s benefit to advanced disease.
Clinical Implications: Sotatercept can be considered as add-on therapy for high-risk PAH patients on maximal background therapy, with monitoring for epistaxis and telangiectasia and ongoing safety surveillance.
Key Findings
- Primary composite of death/transplant/≥24h hospitalization was reduced: 17.4% vs 54.7% (HR 0.24, 95% CI 0.13–0.43).
- Reductions were consistent across components: death 8.1% vs 15.1%, transplantation 1.2% vs 7.0%, hospitalization 9.3% vs 50.0%.
- Most common adverse events with sotatercept were epistaxis and telangiectasia.
Methodological Strengths
- Phase 3 randomized, placebo-controlled design with time-to-event primary endpoint.
- Prespecified interim analysis with strong treatment effect leading to early stop.
Limitations
- Trial stopped early, which may overestimate effect size and limits long-term safety assessment.
- Sample size (n=172) limits subgroup analyses and rare adverse event detection.
Future Directions: Long-term safety and durability of benefit, optimal sequencing with other PAH therapies, and real-world effectiveness in broader populations warrant study.
BACKGROUND: Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The effects of add-on sotatercept in patients with advanced pulmonary arterial hypertension and a high risk of death are unclear. METHODS: In this phase 3 trial, we randomly assigned patients with pulmonary arterial hypertension (WHO functional class III or IV) and a high 1-year risk of death (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management Lite 2 risk score, ≥9) who were receiving the maximum tolerated dose of background therapy to receive add-on sotatercept (starting dose, 0.3 mg per kilogram of body weight; escalated to target dose, 0.7 mg per kilogram) or placebo every 3 weeks. The primary end point was a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening pulmonary arterial hypertension, assessed in a time-to-first-event analysis. RESULTS: A total of 172 patients were included (86 each in the sotatercept and placebo groups). The trial was stopped early on the basis of the efficacy results of a prespecified interim analysis. At least one primary end-point event occurred in 15 patients (17.4%) in the sotatercept group and in 47 patients (54.7%) in the placebo group (hazard ratio, 0.24; 95% confidence interval, 0.13 to 0.43; P<0.001). Death from any cause occurred in 7 patients (8.1%) in the sotatercept group and in 13 patients (15.1%) in the placebo group; lung transplantation in 1 patient (1.2%) and 6 patients (7.0%), respectively; and hospitalization for worsening pulmonary arterial hypertension in 8 patients (9.3%) and 43 patients (50.0%). The most common adverse events with sotatercept were epistaxis and telangiectasia. CONCLUSIONS: Among high-risk adults with pulmonary arterial hypertension who were receiving the maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening pulmonary arterial hypertension than placebo.
2. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.
In this phase 2, double-blind, placebo-controlled RCT, the oral PCSK9 inhibitor AZD0780 reduced LDL-C by 35–51% over 12 weeks on top of moderate-to-high-intensity statins (with/without ezetimibe), with dose-dependent efficacy and safety similar to placebo.
Impact: This represents a potentially paradigm-shifting, once-daily oral approach to PCSK9 inhibition that could improve access and adherence compared with injectables.
Clinical Implications: If outcome benefits are confirmed, an oral PCSK9 inhibitor could be integrated with statins/ezetimibe to achieve LDL-C goals in high-risk patients, potentially improving adherence and expanding use.
Key Findings
- Placebo-corrected LDL-C reduction at 12 weeks: −35.3%, −37.9%, −45.2%, and −50.7% for 1, 3, 10, and 30 mg doses.
- Efficacy was independent of baseline statin intensity and increased guideline goal attainment in a dose-proportional manner.
- Adverse event rates were comparable between AZD0780 (38.2%) and placebo (32.6%).
Methodological Strengths
- Randomized, double-blind, placebo-controlled, multicenter design with dose-ranging.
- Predefined primary endpoint (percent LDL-C change) with adequate sample size for lipid efficacy.
Limitations
- Surrogate endpoint (LDL-C) over 12 weeks; no cardiovascular outcomes assessed.
- Generalizability and long-term safety require further phase 3 trials.
Future Directions: Conduct phase 3 outcomes trials, evaluate long-term safety and adherence, compare head-to-head with injectable PCSK9 inhibitors, and assess cost-effectiveness.
BACKGROUND: Most patients at high-risk for cardiovascular events do not achieve lipid goals advocated by American College of Cardiology/American Heart Association (ACC/AHA) guidelines despite the wide availability of lipid-lowering therapy. AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia. OBJECTIVES: The phase 2 randomized, double-blind, placebo-controlled, multicenter PURSUIT trial evaluated the efficacy and safety of AZD0780 in patients with hypercholesterolemia already on background moderate-to-high-intensity statin treatment. METHODS: Eligible study patients had a fasting low-density lipoprotein cholesterol (LDL-C) level of ≥70 mg/dL (1.8 mmol/L) and <190 mg/dL (4.9 mmol/L), and triglycerides <400 mg/dL on stable dose of moderate- or high-intensity statins, as defined by ACC/AHA or local guidelines, with or without ezetimibe at baseline. The study randomized patients 1:1:1:1:1 to receive AZD0780 1, 3, 10, or 30 mg, or matching placebo, oral once daily, for 12 weeks. The primary efficacy endpoint was percent change of LDL-C from baseline to week 12. Safety and tolerability evaluations included the number of adverse events, vital signs, electrocardiograms, and laboratory assessments. RESULTS: In total, the study randomized 428 patients, of whom 426 started treatment. Patients were 52.1% male, with an average age of 62.4 ± 7.6 years. At week 12, compared with baseline, the placebo-corrected difference in least squares mean percent change of LDL-C for AZD0780 1, 3, 10, and 30 mg vs placebo was -35.3% (95% CI: -43.6% to -26.9%), -37.9% (95% CI:-46.3% to -29.5%), -45.2% (95% CI: -53.5% to -36.9%), and -50.7% (95% CI: -59.0% to -42.4%), respectively. Baseline statin use, moderate vs high intensity, did not alter AZD0780 efficacy. The proportion of patients reaching the ACC/AHA guideline LDL-C goal for high-risk patients increased in a dose-proportional manner. Adverse events compared similarly between the total AZD0780 treatment group (38.2%) and placebo (32.6%). CONCLUSIONS: AZD0780 demonstrated robust, dose-dependent reductions in LDL-C with a favorable safety and tolerability profile supporting further development of this once daily, oral treatment.
3. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.
In 17,087 initially healthy adults followed for 20 years, baseline LDL-C, hsCRP, and Lp(a) independently predicted MACE, with top vs bottom quintile HRs of 1.78, 1.55, and 1.19. Having one, two, or three elevated markers conferred progressively higher risk (HR 1.33, 1.68, 2.41), supporting universal one-time screening.
Impact: This provides long-term, population-level evidence that a combined, one-time measure of LDL-C, hsCRP, and Lp(a) robustly stratifies primary prevention risk, replicating prior US findings and informing screening policy.
Clinical Implications: Universal one-time measurement of LDL-C, hsCRP, and Lp(a) in primary prevention can identify higher-risk individuals and guide earlier lipid-lowering, anti-inflammatory strategies, and Lp(a)-targeted evaluation.
Key Findings
- Top vs bottom quintile HRs for 20-year MACE: LDL-C 1.78, hsCRP 1.55, Lp(a) 1.19 (all adjusted).
- Risk increased additively with the number of elevated biomarkers: HR 1.33 (one), 1.68 (two), 2.41 (three).
- Each biomarker contributed independently to risk across sexes.
Methodological Strengths
- Large prospective cohort with 20-year follow-up and adjudicated MACE.
- Competing-risk and multivariable-adjusted analyses; replication of prior external findings.
Limitations
- Observational design limits causal inference; residual confounding possible.
- Single baseline measurement; biomarker changes over time not captured.
Future Directions: Evaluate implementation strategies for universal screening, cost-effectiveness across health systems, and integration with polygenic risk and imaging to refine prevention.
BACKGROUND AND AIMS: Recent data from a large American cohort of women strongly support universal one-time screening for LDL cholesterol, high-sensitivity C-reactive protein (hsCRP), and lipoprotein(a) [Lp(a)] in primary prevention. This study addresses the validity and generalizability of this novel primary prevention strategy in a large prospective European cohort of initially healthy men and women. METHODS: Plasma levels of LDL cholesterol, hsCRP, and Lp(a) were measured at study entry in 17 087 participants from the EPIC-Norfolk study who were subsequently followed over a period of 20 years for major adverse cardiovascular events (MACEs). Competing risk- and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident MACE across quintiles of each biomarker and sought evidence of independent as well as additive effects over time were calculated. RESULTS: During the 20-year follow-up, a total of 3249 MACEs occurred. Increasing quintiles of baseline LDL cholesterol, hsCRP, and Lp(a) all predicted 20-year risks; the multivariable-adjusted HRs in a comparison of the top to bottom quintile were 1.78 (95% CI: 1.57-2.00) for LDL cholesterol, 1.55 (95% CI: 1.37-1.74) for hsCRP, and 1.19 (95% CI: 1.07-1.33) for Lp(a). Compared with individuals with no biomarker elevations, the multivariable-adjusted HRs for incident MACE were 1.33, 1.68, and 2.41 for those with one, two, or three biomarkers in the top quintile, respectively (all P < .001). Each biomarker demonstrated independent contributions to overall risk and findings were consistent in analyses stratified by sex. CONCLUSIONS: A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy European men and women was predictive of incident MACE during a 20-year period. These data replicate findings from a recent American cohort and strongly support universal screening for all three biomarkers in primary prevention.